Kemp Dolliver
Stock Analyst at Brookline Capital
(0.28)
# 4,091
Out of 4,829 analysts
17
Total ratings
25%
Success rate
-29.26%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $4.06 | +318.72% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $1.16 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.51 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.79 | +355.75% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.88 | +1,150.00% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.59 | +1,874.84% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $3.71 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $79.66 | +25.53% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.95 | +2,822.03% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.81 | +789.68% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.89 | +283.44% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.95 | +738.22% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.99 | +471.86% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $4.06
Upside: +318.72%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.16
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.51
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.79
Upside: +355.75%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.88
Upside: +1,150.00%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.59
Upside: +1,874.84%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $3.71
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $79.66
Upside: +25.53%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.95
Upside: +2,822.03%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.81
Upside: +789.68%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $4.89
Upside: +283.44%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.95
Upside: +738.22%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.99
Upside: +471.86%